<DOC>
	<DOCNO>NCT01111461</DOCNO>
	<brief_summary>To assess objective response rate ( ORR : complete response + partial response [ CR+ PR ] ) E7080 subject unresectable endometrial cancer disease progression follow platinum-based , first-line chemotherapy . .</brief_summary>
	<brief_title>Study Lenvatinib Subjects With Advanced Endometrial Cancer Disease Progression</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically confirm diagnosis endometrial carcinoma . 2 . Radiographic evidence disease progression accord modify RECIST 1.1 1 prior systemic , platinumbased chemotherapy regimen recurrent metastatic primary unresectable endometrial carcinoma surgical radiotherapy treatment option exists . 3 . Measureable disease meeting follow criterion : At least 1 lesion great 1.0 cm long diameter nonlymph node great 1.5 cm shortaxis diameter lymph node serially measureable accord modified RECIST 1.1 use computerized tomography / magnetic resonance imaging . Lesions external beam radiotherapy ( EBRT ) locoregional therapy radiofrequency ablation must show evidence progressive disease base modified RECIST 1.1 deem target lesion . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status less 2 . 5 . Adequate control blood pressure ( BP ) without antihypertensive medication , define BP le 150/90 mmHg screen change antihypertensive medication within 1 week prior Screening Visit . 6 . Adequate renal function define calculated creatinine clearance great 30 mL/min per Cockcroft Gault formula . 7 . Adequate bone marrow , blood coagulation , liver function , define study protocol . 8 . Negative serum urine pregnancy test woman reproductive potential . Exclusion criterion : 1 . Brain leptomeningeal metastasis , include stable metastasis . 2 . More 1 prior systemic chemotherapy regimen recurrent metastatic primary unresectable endometrial carcinoma treatment target vascular endothelial growth factor ( VEGF ) direct angiogenesis . No restriction regard prior adjuvant chemotherapy hormonal therapy . 3 . Prior systemic antitumor therapy within 3 week . 4 . Not fully recover prior radiotherapy base investigator judgement . 5 . Participants great 1+ proteinuria urine dipstick test undergo 24hour urine collection quantitative assessment proteinuria . Participants great 1 gm ineligible . 6 . Significant cardiovascular impairment : history congestive heart failure great New York Heart Association Class II ; unstable angina ; myocardial infarction stroke within 6 month first dose study drug ; cardiac arrhythmia require medical treatment . 7 . Prolongation QTc interval great 480 msec . 8 . Bleeding disorder thrombotic disorder require anticoagulant therapy , warfarin , similar agent require therapeutic INR monitoring ( treatment low molecular weight heparin [ LMWH ] allow ) . 9 . Active hemoptysis within 3 week prior first dose study drug . 10 . Females pregnant breast feeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Advanced Endometrial Cancer</keyword>
</DOC>